Overview

Low-Dose Weekly vs High-Dose Cisplatin

Status:
Recruiting

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This study is a prospective open-label randomized clinical trial. Following informed consent eligible LASCCHN patients (n=100) planned for CRT will be stratified by tumor p16 status and then randomized in a 1:1 fashion to either concurrent HD cisplatin or concurrent weekly LD cisplatin.

Phase:

N/A

Details

Lead Sponsor:

Lawson Health Research Institute

Treatments:

Cisplatin